Digital solutions for personalized medicine: The future of pharmacogenomics

Pharmacogenomics, the study of how genetic variations influence individual drug responses, represents a cornerstone of personalized medicine. Recent advancements in digital health technologies have significantly enhanced the feasibility of integrating pharmacogenomics into clinical practice. Tools such as Artificial Intelligence (AI), big data analytics, and blockchain have transformed the ways genetic data are analyzed, stored, and applied in healthcare. These innovations enable the delivery of precise drug therapies, mitigate adverse drug reactions, and enhance overall patient outcomes. Despite the substantial promise, challenges related to data privacy, interoperability, cost, and equitable access persist. This paper explores the role of digital technologies in advancing pharmacogenomics, highlighting their transformative potential and offering strategies to address existing barriers.

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-02-19
DOI
https://doi.org/10.5281/zenodo.16759198
Primary Topic
Pharmacogenetics and Drug Metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Digital solutions for personalized medicine: The future of pharmacogenomics

Zenodo (CERN European Organization for Nuclear Research)
Pharmacogenetics and Drug Metabolism
article

Digital solutions for personalized medicine: The future of pharmacogenomics

article en

Abstract

Pharmacogenomics, the study of how genetic variations influence individual drug responses, represents a cornerstone of personalized medicine. Recent advancements in digital health technologies have significantly enhanced the feasibility of integrating pharmacogenomics into clinical practice. Tools such as Artificial Intelligence (AI), big data analytics, and blockchain have transformed the ways genetic data are analyzed, stored, and applied in healthcare. These innovations enable the delivery of precise drug therapies, mitigate adverse drug reactions, and enhance overall patient outcomes. Despite the substantial promise, challenges related to data privacy, interoperability, cost, and equitable access persist. This paper explores the role of digital technologies in advancing pharmacogenomics, highlighting their transformative potential and offering strategies to address existing barriers.

Zenodo (CERN European Organization for Nuclear Research)
Princess Nourah bint Abdulrahman University (SA), Qassim University (SA), Taif University (SA), Sulaiman Al Rajhi Colleges (SA), University of Ha'il (SA), University of Hafr Al-Batin (SA), Ministry of Health (KW), University of Tabuk (SA), Imam Abdulrahman Bin Faisal University (SA), King Khalid University (SA), Jazan University (SA)
Partnerships for the goals
Openalex Percentile: Top 45%
Pharmacogenetics and Drug Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.